Cargando…
Opinion controversy to chromium picolinate therapy’s safety and efficacy: ignoring ‘anecdotes’ of case reports or recognising individual risks and new guidelines urgency to introduce innovation by predictive diagnostics?
Due to the important physiologic function of trivalent chromium in glucose/insulin homeostasis, some commercial organisations promote Cr(3+) supplements in maintaining proper carbohydrate and lipid metabolism; regulation of reducing carbohydrate carvings and appetite; prevention of insulin resistanc...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3515400/ https://www.ncbi.nlm.nih.gov/pubmed/23039227 http://dx.doi.org/10.1186/1878-5085-3-11 |
_version_ | 1782252171512774656 |
---|---|
author | Golubnitschaja, Olga Yeghiazaryan, Kristina |
author_facet | Golubnitschaja, Olga Yeghiazaryan, Kristina |
author_sort | Golubnitschaja, Olga |
collection | PubMed |
description | Due to the important physiologic function of trivalent chromium in glucose/insulin homeostasis, some commercial organisations promote Cr(3+) supplements in maintaining proper carbohydrate and lipid metabolism; regulation of reducing carbohydrate carvings and appetite; prevention of insulin resistance and glucose intolerance; regulation of body composition, including reducing fat mass and increasing lean body mass; optimal body building for athletes; losing weight; treatment of atypical depression as an antidepressant; and prevention of obesity and type 2 diabetes mellitus. On one hand, case reports are commented as ‘nonevidence-based anecdotes’. On the other hand, a number of independent studies warn against adverse health outcomes assigned to chromium picolinate (CrPic) dietary application. This review analyses opinion controversies, demonstrates highly individual reactions towards CrPic dietary supplements and highlights risks when the dietary supplements are used freely as therapeutic agents, without application of advanced diagnostic tools to predict individual outcomes. |
format | Online Article Text |
id | pubmed-3515400 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2012 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-35154002012-12-06 Opinion controversy to chromium picolinate therapy’s safety and efficacy: ignoring ‘anecdotes’ of case reports or recognising individual risks and new guidelines urgency to introduce innovation by predictive diagnostics? Golubnitschaja, Olga Yeghiazaryan, Kristina EPMA J Review Due to the important physiologic function of trivalent chromium in glucose/insulin homeostasis, some commercial organisations promote Cr(3+) supplements in maintaining proper carbohydrate and lipid metabolism; regulation of reducing carbohydrate carvings and appetite; prevention of insulin resistance and glucose intolerance; regulation of body composition, including reducing fat mass and increasing lean body mass; optimal body building for athletes; losing weight; treatment of atypical depression as an antidepressant; and prevention of obesity and type 2 diabetes mellitus. On one hand, case reports are commented as ‘nonevidence-based anecdotes’. On the other hand, a number of independent studies warn against adverse health outcomes assigned to chromium picolinate (CrPic) dietary application. This review analyses opinion controversies, demonstrates highly individual reactions towards CrPic dietary supplements and highlights risks when the dietary supplements are used freely as therapeutic agents, without application of advanced diagnostic tools to predict individual outcomes. BioMed Central 2012-10-07 /pmc/articles/PMC3515400/ /pubmed/23039227 http://dx.doi.org/10.1186/1878-5085-3-11 Text en Copyright ©2012 Golubnitschaja and Yeghiazaryan; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Review Golubnitschaja, Olga Yeghiazaryan, Kristina Opinion controversy to chromium picolinate therapy’s safety and efficacy: ignoring ‘anecdotes’ of case reports or recognising individual risks and new guidelines urgency to introduce innovation by predictive diagnostics? |
title | Opinion controversy to chromium picolinate therapy’s safety and efficacy: ignoring ‘anecdotes’ of case reports or recognising individual risks and new guidelines urgency to introduce innovation by predictive diagnostics? |
title_full | Opinion controversy to chromium picolinate therapy’s safety and efficacy: ignoring ‘anecdotes’ of case reports or recognising individual risks and new guidelines urgency to introduce innovation by predictive diagnostics? |
title_fullStr | Opinion controversy to chromium picolinate therapy’s safety and efficacy: ignoring ‘anecdotes’ of case reports or recognising individual risks and new guidelines urgency to introduce innovation by predictive diagnostics? |
title_full_unstemmed | Opinion controversy to chromium picolinate therapy’s safety and efficacy: ignoring ‘anecdotes’ of case reports or recognising individual risks and new guidelines urgency to introduce innovation by predictive diagnostics? |
title_short | Opinion controversy to chromium picolinate therapy’s safety and efficacy: ignoring ‘anecdotes’ of case reports or recognising individual risks and new guidelines urgency to introduce innovation by predictive diagnostics? |
title_sort | opinion controversy to chromium picolinate therapy’s safety and efficacy: ignoring ‘anecdotes’ of case reports or recognising individual risks and new guidelines urgency to introduce innovation by predictive diagnostics? |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3515400/ https://www.ncbi.nlm.nih.gov/pubmed/23039227 http://dx.doi.org/10.1186/1878-5085-3-11 |
work_keys_str_mv | AT golubnitschajaolga opinioncontroversytochromiumpicolinatetherapyssafetyandefficacyignoringanecdotesofcasereportsorrecognisingindividualrisksandnewguidelinesurgencytointroduceinnovationbypredictivediagnostics AT yeghiazaryankristina opinioncontroversytochromiumpicolinatetherapyssafetyandefficacyignoringanecdotesofcasereportsorrecognisingindividualrisksandnewguidelinesurgencytointroduceinnovationbypredictivediagnostics |